Priothera Announces First Patients Enrolled in Pivotal MO-TRANS Global Phase IIb/III Study with Mocravimod as an Adjunctive and Maintenance Therapy for Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

By
Noshin Noorjahan
-
0
152
Priothera announced that the first patients have been enrolled in the pivotal MO-TRANS global Phase IIb/III study evaluating mocravimod in AML patients undergoing allogeneic hematopoietic cell transplant.
[Priothera ( Cision US Inc.)]
Press Release